ViaDerma, Inc. (VDRM)
| Previous Close | 0.0100 |
| Open | 0.0095 |
| Bid | 0.0090 x 0 |
| Ask | 0.0093 x 0 |
| Day's Range | 0.0086 - 0.0098 |
| 52 Week Range | 0.0030 - 0.0150 |
| Volume | |
| Avg. Volume | 2,499,545 |
| Market Cap | 11.227M |
| Beta (5Y Monthly) | -0.43 |
| PE Ratio (TTM) | 0.03 |
| EPS (TTM) | 0.2800 |
| Earnings Date | Dec 16, 2024 - Dec 31, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireViaDerma, Inc. Reports Strong Financial Results for Q2 2024, Achieving Positive Net Income and Significant Cash Flow Growth
LOS ANGELES, Oct. 03, 2024 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Pink: VDRM), an innovator in transdermal drug delivery and topical antibiotic products, announced its financial results for the second quarter and six-month period ending June 30, 2024. The company delivered a strong financial performance with notable revenue consistency, positive net income, and a robust increase in cash reserves. Financial Highlights for Q2 2024: Revenue: ViaDerma maintained steady revenues of $300,191 for the
- GlobeNewswire
ViaDerma Completes First Shipment of 500,000 Units to Nigeria
A second shipment of 500,000 units is expected to be made by the end of OctoberLOS ANGELES, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC: VDRM), a specialty pharmaceutical company known for developing innovative transdermal drug delivery systems, is pleased to announce the successful completion of its first shipment of 500,000 units of its flagship product, a tetracycline based topical antibiotic to Nigeria. The shipment was sent out as planned before the end of August 2024. This miles
